Identification of the α2 chain of interleukin‐13 receptor as a potential biomarker for predicting castration resistance of prostate cancer using patient‐derived xenograft models

Background Several treatment strategies use upfront chemotherapy or androgen receptor axis‐targeting therapies for metastatic prostate cancer. However, there are no useful biomarkers for selecting appropriate patients who urgently require these treatments. Methods Novel patient‐derived xenograft (PD...

Full description

Saved in:
Bibliographic Details
Published in:Cancer reports 2023-02, Vol.6 (2), p.e1701-n/a
Main Authors: Nagai, Takahiro, Terada, Naoki, Fujii, Masato, Nagata, Yasuhisa, Nakahara, Kozue, Mukai, Shoichiro, Okasho, Kosuke, Kamiyama, Yuki, Akamatsu, Shusuke, Kobayashi, Takashi, Iida, Kei, Denawa, Masatsugu, Hagiwara, Masatoshi, Inoue, Takahiro, Ogawa, Osamu, Kamoto, Toshiyuki
Format: Article
Language:English
Subjects:
Androgens
Antigens
biomarker
Biomarkers
castration resistance
Cytokines
Gene expression
Genomes
Heterografts
Humans
Interleukin-13 Receptor alpha2 Subunit - therapeutic use
Interleukin‐13 receptor α2
Male
Metastasis
Orchiectomy
Original
Patients
patient‐derived xenograft
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - pathology
Proteins
Transplants & implants
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Several treatment strategies use upfront chemotherapy or androgen receptor axis‐targeting therapies for metastatic prostate cancer. However, there are no useful biomarkers for selecting appropriate patients who urgently require these treatments. Methods Novel patient‐derived xenograft (PDX) castration‐sensitive and ‐resistant models were established and gene expression patterns were comprehensively compared. The function of a gene highly expressed in the castration‐resistant models was evaluated by its overexpression in LNCaP prostate cancer cells. Protein expression in the tumors and serum of patients was examined by immunohistochemistry and ELISA, and correlations with castration resistance were analyzed. Results Expression of the α2 chain of interleukin‐13 receptor (IL13Rα2) was higher in castration‐resistant PDX tumors. LNCaP cells overexpressing IL13Rα2 acquired castration resistance in vitro and in vivo. In tissue samples, IL13Rα2 expression levels were significantly associated with castration‐resistant progression (p 
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.1701